

knoell looks to next 25 years of animal health research services IHS Markit

20 Jun 2023 - Animal Health | Headline Analysis

knoell believes it is well-positioned to build on its first 25 years of being a notable services partner in animal health.

The contract research organization (CRO) has firmly established itself as a recognized “go-to global partner” for product development and regulatory support in the animal health sector, with a customer roster featuring companies of all sizes – from start-ups to multinationals.

The company has previously been able to [build a name for itself](#) in the animal health space by acquiring Cyton Biosciences in 2010 and Triveritas in 2020. These deals brought two well-established industry CROs together under the umbrella of knoell Animal Health and helped the group put together an experienced management team. knoell is led by Karolina Bate (managing director, who was previously with Cyton), Mel Munro (global regulatory science lead, formerly with Triveritas) and Colin McClean (global clinical lead, previously with Charles River Laboratories).

Dr Bate remarked: “As a consultancy group, we have endeavoured to adapt to the ever-changing landscape of the animal health market. Early growth as European CROs in the 2000s saw rapid expansion into the US to deliver regulatory strategy and clinical trials. The last decade has been characterized by global mergers and acquisitions, and our integration by knoell has provided opportunities to globalize the team – to be a one-stop global service provider to the animal health market.”

In 2022, knoell’s global network delivered client projects in 46 countries across five continents. This included programs across Europe, the US, Canada, Brazil, Asia (including China and Japan), India, Australia and New Zealand. The business worked on projects for 50 new clients, in addition to over 200 existing customers.

Mr McClean noted: “Following successful integration, the team are continuing to professionalize and strengthen to meet client demand with strategic personnel recruitments in 2022, bringing with them over 70 years’ industry experience. 2023 has started off equally strong, with all animal health offices in Europe, US and Asia experiencing expansion.”

knoell is currently focused on expanding its biologicals development capacity and clinical teams in both the EU and US, appointing 10 new employees in the last 12 months alone. These include Cari Ledbetter in the US and Callum Scott in Europe.

Dr Munro added: “The veterinary sector has experienced an exponential growth in the development of vaccines, biologics and novel biotherapeutics including monoclonal antibodies, gene therapy and novel platform technologies, as well as regenerative medicines, oncology and allergy products. Expanding our in-house biologicals expertise to meet client demand in the EU and US continues to be a necessity. Cari and Callum join with over 35 years of biologicals and drug development experience between them.

“Cari has previously worked for Zoetis and Perrigo in biologics regulatory and clinical positions, while Callum has been developing vaccines for aquaculture and allergy, most recently at Allergy Therapeutics and Benchmark Animal Health.”

Analyst Contact Details: Joseph Harvey